tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Travere Therapeutics Inc

TVTX
Add to Watchlist
55.890USD
-1.390-2.43%
Close 07-31 16:00（ET）Quotes delayed by 15 min
5.16BMarket Cap
LossP/E TTM

Travere Therapeutics Inc

55.890
-1.390-2.43%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

TVTX Financials

See Travere Therapeutics Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Travere Therapeutics Inc Earnings Date

Latest Release
Aug 4, 2026
EPS / Forecast
--/-0.14
Revenue / Forecast
--/159.59M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
490.73M
110.45%
EPS(YoY)
-0.29
92.97%
Analyst Rating
BUY
2026/08/01
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
13.44%-0.40
104.17%0.03
140.88%0.29
84.22%-0.14
73.55%-0.47
38.50%-0.72
-135.67%-0.70
19.60%-0.91
-39.29%-1.76
-15.00%-1.18
--1.98
---1.13
---1.27
---1.02
---3.34
----
----
----
----
----
Revenue
55.63%127.20M
73.41%129.69M
162.11%164.86M
111.49%114.45M
97.54%81.73M
65.98%74.79M
69.56%62.90M
68.08%54.12M
33.95%41.37M
53.58%45.06M
32.13%37.09M
-40.56%32.20M
-36.30%30.89M
-48.75%29.34M
-58.84%28.07M
-0.82%54.17M
2.28%48.49M
12.29%57.25M
33.40%68.22M
12.78%54.62M
Net Profit
10.00%-37.10M
104.53%2.73M
146.90%25.71M
81.88%-12.76M
69.70%-41.23M
33.17%-60.26M
-136.36%-54.81M
17.78%-70.41M
-57.60%-136.06M
-36.99%-90.17M
316.40%150.74M
-27.74%-85.63M
-13.64%-86.33M
-27.63%-65.82M
-95.45%-69.66M
-71.82%-67.03M
-41.03%-75.97M
57.60%-51.57M
-58.05%-35.64M
-49.65%-39.01M
Net Margin
42.95%-28.78%
78.96%-16.95%
117.91%15.59%
91.34%-11.14%
84.65%-50.44%
59.01%-80.59%
63.82%-87.05%
59.35%-128.71%
-5.11%-328.61%
32.64%-196.62%
---240.57%
---316.60%
---312.63%
---291.88%
---306.83%
----
----
----
----
----
Gross Margin
4.45%98.47%
1.50%98.03%
1.67%99.04%
2.58%98.67%
-2.17%94.28%
7.47%96.59%
0.92%97.41%
0.73%96.19%
11.30%96.36%
-7.39%89.87%
--96.53%
--95.49%
--86.58%
--97.04%
--95.57%
----
----
----
----
----
Debt to assets ratio
-18.70%56.21%
-19.25%51.51%
-22.97%57.81%
-0.30%68.40%
21.46%69.14%
33.39%63.79%
65.87%75.05%
34.24%68.61%
22.36%56.92%
-14.36%47.82%
--45.25%
--51.11%
--46.52%
--55.84%
--51.65%
----
----
----
----
----
Income Statement
Revenue
55.63%127.20M
73.41%129.69M
162.11%164.86M
111.49%114.45M
97.54%81.73M
65.98%74.79M
69.56%62.90M
68.08%54.12M
33.95%41.37M
53.58%45.06M
32.13%37.09M
-40.56%32.20M
-36.30%30.89M
-48.75%29.34M
-58.84%28.07M
-0.82%54.17M
2.28%48.49M
12.29%57.25M
33.40%68.22M
12.78%54.62M
Operating profit
13.50%-36.91M
45.35%-32.43M
144.50%24.93M
81.13%-12.65M
42.15%-42.67M
28.37%-59.33M
39.49%-56.03M
35.50%-67.05M
24.23%-73.77M
4.46%-82.84M
-12.08%-92.58M
-71.69%-103.95M
-70.67%-97.37M
-77.34%-86.70M
-362.85%-82.60M
-79.09%-60.54M
-46.42%-57.05M
-93.91%-48.89M
-24.37%-17.85M
-79.58%-33.81M
Net Profit
10.00%-37.10M
104.53%2.73M
146.90%25.71M
81.88%-12.76M
69.70%-41.23M
33.17%-60.26M
-136.36%-54.81M
17.78%-70.41M
-57.60%-136.06M
-36.99%-90.17M
316.40%150.74M
-27.74%-85.63M
-13.64%-86.33M
-27.63%-65.82M
-95.45%-69.66M
-71.82%-67.03M
-41.03%-75.97M
57.60%-51.57M
-58.05%-35.64M
-49.65%-39.01M
Balance Sheet
Current assets
4.95%392.68M
5.01%437.56M
14.28%371.11M
2.87%379.57M
-22.22%374.17M
-32.44%416.70M
-52.68%324.74M
-31.93%368.98M
-20.47%481.08M
26.79%616.77M
28.31%686.23M
-7.62%542.05M
-4.15%604.90M
-16.54%486.44M
-7.64%534.84M
6.73%586.78M
11.69%631.09M
42.01%582.83M
16.36%579.08M
8.75%549.80M
Total current liabilities
-31.25%125.44M
-20.35%159.90M
-28.92%135.07M
56.30%189.54M
5.33%182.46M
12.84%200.75M
36.29%190.04M
-10.64%121.27M
32.60%173.23M
25.14%177.91M
6.41%139.43M
9.01%135.71M
9.35%130.65M
14.57%142.16M
15.79%131.03M
28.37%124.49M
40.53%119.47M
33.92%124.09M
50.03%113.16M
38.67%96.98M
Total assets
1.16%555.19M
1.86%605.19M
6.77%538.58M
0.76%555.31M
-17.29%548.80M
-24.69%594.13M
-39.44%504.41M
-25.16%551.12M
-17.90%663.55M
17.30%788.91M
14.68%832.85M
-5.52%736.43M
-2.44%808.23M
-13.40%672.59M
-6.30%726.22M
4.38%779.49M
8.42%828.40M
27.85%776.63M
11.97%775.08M
10.03%746.77M
Total liabilities
-11.53%456.46M
-8.35%490.36M
-13.06%465.02M
-2.50%522.56M
-12.47%515.98M
-9.02%535.05M
-3.29%534.86M
-13.54%535.97M
-4.78%589.48M
-6.61%588.10M
-11.58%553.08M
-0.46%619.94M
-0.19%619.09M
32.71%629.73M
33.75%625.54M
50.26%622.78M
54.54%620.26M
19.76%474.52M
19.68%467.70M
15.11%414.46M
Total equity
200.79%98.73M
94.37%114.83M
341.56%73.56M
116.19%32.75M
-55.69%32.82M
-70.58%59.08M
-110.89%-30.45M
-87.00%15.15M
-60.84%74.07M
368.62%200.81M
177.89%279.77M
-25.67%116.48M
-9.13%189.14M
-85.82%42.85M
-67.25%100.68M
-52.84%156.71M
-42.61%208.14M
43.04%302.11M
1.98%307.37M
4.29%332.30M
Cash Flow Statement
Net operating income
4.33%-40.37M
311.93%60.68M
133.64%14.32M
112.48%4.98M
64.51%-42.19M
55.52%-28.63M
61.51%-42.56M
42.37%-39.93M
-46.58%-118.90M
-17.81%-64.37M
-179.75%-110.57M
-88.28%-69.30M
-46.63%-81.12M
-103.30%-54.64M
-223.27%-39.52M
-666.59%-36.81M
-108.96%-55.32M
-93.78%-26.88M
376.07%32.06M
200.67%6.50M
Net investment
-47.81%21.55M
-30.54%-104.84M
87.73%86.59M
-83.05%4.85M
-60.64%41.29M
-341.79%-80.31M
163.31%46.13M
221.47%28.61M
383.21%104.90M
50.47%-18.18M
-822.85%-72.86M
39.76%-23.55M
-211.68%-37.04M
-597.98%-36.70M
-69.01%10.08M
45.55%-39.10M
131.37%33.16M
105.87%7.37M
175.33%32.52M
-205.91%-71.81M
Net financing
13.07%4.20M
-80.82%26.68M
-142141.30%-65.34M
88.62%1.48M
808.19%3.72M
36223.50%139.12M
112.30%46.00K
-69.03%782.00K
-100.24%-525.00K
-30.49%383.00K
-116.42%-374.00K
203.85%2.52M
91.02%217.60M
-98.52%551.00K
-26.04%2.28M
-14.33%831.00K
-42.02%113.91M
44.38%37.25M
604.81%3.08M
-99.11%970.00K

FAQs

What is the total revenue of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its total revenue reached 490.73M, with a year-on-year change of 233.18M.

What are the current assets of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its current assets were 437.56M, with a year-on-year change of 5.01.

What are the total assets of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its total assets of Travere Therapeutics Inc were 605.19M, with a year-on-year change of 1.86.

What are the total liabilities of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its total liabilities of Travere Therapeutics Inc were 490.36M, with a year-on-year change of -8.35.

What is the total equity of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its total equity of Travere Therapeutics Inc was 114.83M, with a year-on-year change of 94.37.

What is the net operating income of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its net operating income of Travere Therapeutics Inc was -62.82M, with a year-on-year change of 75.48.

What is the net investment of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its net investment of Travere Therapeutics Inc was 27.89M, with a year-on-year change of -71.92.

What is the net financing of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its net financing of Travere Therapeutics Inc was -33.47M, with a year-on-year change of -124.00.

What is the Earnings Per Share (EPS) of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -0.29, with a year-on-year change of 92.97.

What is the net income of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its net income was -25.55M, with a year-on-year change of 92.06.

What is the net margin of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its net profit margin was -10.24, with a year-on-year change of 92.55.

What is the gross margin of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its gross margin was 97.89, with a year-on-year change of 1.26.

What is the debt-to-asset ratio of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its debt-to-asset ratio was 51.51, with a year-on-year change of -19.25.

What is the Return on Equity (ROE) of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its Return on Equity (ROE) was -57.80, with a year-on-year change of 76.57.

What is the Return on Assets (ROA) of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its Return on Assets (ROA) was -8.38, with a year-on-year change of 81.92.

What is the operating profit of Travere Therapeutics Inc?

According to Travere Therapeutics Inc's FY2025 earnings report, its operating profit was -62.82M, with a year-on-year change of 75.48.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy